Andrew Oxtoby is Chief Commercial Officer at Aimmune Therapeutics, Inc. (AIMT). They have made 1 open-market trade across 1 company since 2020, most recently 2020-10-13.
CIK 0001765473
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $44K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AIMT | 26,595 | $917K |
Shares reported on the most recent Form 4, priced at the 2020-09-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIMT | BUY | 2020-03-13 | 2020-03-17 | $14.76 | $44K | +29.6% | +41.2% | +72.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.